Clinical Trial Closeup
A potential gene therapy to treat Stargardt
Phase II results identify patients with macular degeneration phenotype may benefit most from the investigative transgene therapy.
Transgene shows restorative properties in nAMD
4D-150 is an intravitreal dual transgene genetic medicine that expresses both aflibercept and an mRNAi sequence that inhibits intracellular expression of VEGF-C.
Potential of low-light therapy for dry AMD
Trial shows effectiveness of the Valeda Light Delivery System photobiomodulation platform.
Reviving dormant photoreceptors in LCA1
The gene therapy ATSN-101 has demonstrated safety and shown signals of efficacy in restoring vision in Leber congenital amaurosis.
A pill to head off worsening of DRSS
A Phase III trial is on deck for the oral Ref-1 inhibitor APX3330 after a Phase IIb study showed a potential benefit.
Axitinib implant shows early potential
Interim results from Phase I trial of OTX-TKI, a bioresorbable hydrogel platform using a tyrosine kinase inhibitor.
Senolytic therapy: ‘Entirely new paradigm’
A look at UBX1325, a small-molecule B-cell inhibitor that targets the proteins senescent cells feed on for survival.
Sustained-release sunitinib comes to retina
A closer look at the extension study of GB-102 for treatment of neovascular age-related macular degeneration.
A potential stem-cell solution for GA
Trial shows safety of a biosynthetic patch inserted in a subretinal bleb in an outpatient procedure.
Targeting headwaters of classical pathway
The IgG antibody fragment ANX007 aims to disrupt the cascade that leads to geographic atrophy at the initiating molecule.
How THR-149 targets alternate pathway
The plasma kallikrein inhibitor is being investigated to treat diabetic macular edema that doesn’t respond to anti-VEGF therapy.
TKI vorolanib implant shows early signal
DAVIO Phase I results of EYP-1901 show reduced treatment burden in age-related macular degeneration.
Targeted approach to pan-VEGF inhibition
A suprachoroidal formulation of axitinib, approved for renal cell carcinoma, may have potential for treating neovascular AMD.
A potential disrupter of GA progression
A post-hoc analysis shows that pegcetacoplan may disrupt the complement pathway to potentially stabilize nascent or early atrophy.
PDS with ranibizumab: It’s in the technique
A closer look at Archway results and ‘a few important details’ for the implantation procedure that drives outcomes.
Targeting a key GA factor at its source
Investigational treatment FB-LRX targets complement factor B further up the complement cascade.
Targeting a novel enzyme in GA
An investigative antibody aims to inhibit HtrA1 that contributes to progression of geographic atrophy.
Potential of KSI-301 to extend treatment
The latest results reported efficacy up to five months after the last loading dose.
Modulating macrophages to target GA
Investigational candidate aims to change macrophage behavior in management of dry age-related macular degeneration.
Wet AMD gene therapy shows promise
Phase I/IIa results of RGX-314 confirm protein uptake over months.
Current Issue
Continuing Medical Education
Additional Publications
Learn More about Stargardt Disease
Watch the webinar
Earlier Treatment Can Matter for Macular Edema Following Retinal Vein Occlusion
Treating Chronic Inflammation Associated With Uveitis Affecting the Posterior Segment in a Retina Setting with YUTIQ
GA: Recognizing the Burden
Treatment of Proliferative Diabetic Retinopathy
Improving Wet AMD Outcomes With a Fellow Eye Strategy
